Stock A340570 T&L CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials T&L Co., Ltd.

Equities

A340570

KR7340570001

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
65,300 KRW -1.21% Intraday chart for T&L Co., Ltd. +10.87% +63.25%
2023 Tranche Update on T&L Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022. CI
2023 Tranche Update on T&L Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 173,939 384,454 292,207 322,880 527,102 - -
Enterprise Value (EV) 2 173.9 347.6 258.6 322.9 448.3 416.6 378.2
P/E ratio - 14.2 x 13.9 x 11.8 x 14.7 x 11.6 x 10.3 x
Yield - 0.85% 1.24% - 1.07% 1.34% 1.68%
Capitalization / Revenue 4.28 x 5.35 x 3.58 x 2.8 x 3.77 x 3.08 x 2.57 x
EV / Revenue 4.28 x 4.83 x 3.17 x 2.8 x 3.2 x 2.43 x 1.85 x
EV / EBITDA - 14.5 x 9.79 x 9.6 x 10.3 x 7.52 x 6.01 x
EV / FCF - 103 x -440 x - 19.5 x 13.4 x -
FCF Yield - 0.97% -0.23% - 5.13% 7.44% -
Price to Book - 4.27 x 2.77 x - 3.27 x 2.62 x 2.18 x
Nbr of stocks (in thousands) 8,128 8,128 8,072 8,072 8,072 - -
Reference price 3 21,400 47,300 36,200 40,000 65,300 65,300 65,300
Announcement Date 02/02/21 09/02/22 14/03/23 02/02/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 40.63 71.9 81.58 115.5 139.9 171.2 204.9
EBITDA 1 - 24.02 26.41 33.64 43.55 55.4 62.9
EBIT 1 9.592 22.33 24.31 30.84 40.65 51.7 59.5
Operating Margin 23.61% 31.06% 29.8% 26.71% 29.06% 30.2% 29.04%
Earnings before Tax (EBT) 1 - 23.43 25.56 33.06 43.55 54.95 61.9
Net income 1 - 19.45 21.12 27.44 36.2 45.6 51.3
Net margin - 27.06% 25.89% 23.76% 25.88% 26.64% 25.04%
EPS 2 - 3,334 2,602 3,399 4,453 5,614 6,316
Free Cash Flow 3 - 3,372 -587.5 - 23,000 31,000 -
FCF margin - 4,690.55% -720.18% - 16,440.31% 18,107.48% -
FCF Conversion (EBITDA) - 14,040.98% - - 52,812.86% 55,956.68% -
FCF Conversion (Net income) - 17,335.11% - - 63,535.91% 67,982.46% -
Dividend per Share 2 - 400.0 450.0 - 700.0 875.0 1,100
Announcement Date 02/02/21 09/02/22 14/03/23 02/02/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 18.28 22.32 14.79 23.62 20.46 22.71 27.04 36.45 30.03 21.94 29.15 39.2 34.4 37.15
EBITDA - - - - - - - - - - - - - -
EBIT 1 6.967 5.609 4.672 8.253 6.109 5.276 8.852 12.57 8.435 0.9842 9.6 13.5 10.55 6.9
Operating Margin 38.12% 25.13% 31.58% 34.94% 29.85% 23.24% 32.74% 34.48% 28.09% 4.49% 32.93% 34.44% 30.67% 18.57%
Earnings before Tax (EBT) 1 7.415 5.744 5.021 9.038 6.85 4.651 9.509 12.96 9.608 0.98 11 12.7 12.4 6.4
Net income 1 6.161 4.755 4.197 7.555 5.497 4.28 7.859 10.04 7.65 1.893 9.1 10.6 10.3 5.3
Net margin 33.71% 21.3% 28.38% 31.99% 26.86% 18.85% 29.06% 27.53% 25.48% 8.63% 31.22% 27.04% 29.94% 14.27%
EPS - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 28/10/21 09/02/22 13/05/22 26/07/22 11/11/22 14/03/23 15/05/23 11/08/23 14/11/23 02/02/24 - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 36.8 33.6 - 78.8 111 149
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 2 - 3,372 -588 - 23,000 31,000 -
ROE (net income / shareholders' equity) - 24% 21.5% 23.3% 24.9% 25.2% 23.1%
ROA (Net income/ Total Assets) - 21.9% 19.6% - 22.6% 23% 21.5%
Assets 1 - 88.88 107.7 - 160.5 198.3 238.6
Book Value Per Share 3 - 11,084 13,050 - 19,982 24,900 30,003
Cash Flow per Share 3 - 2,338 1,896 - 4,841 6,052 6,749
Capex 1 - 15.6 16 - 9.25 10.5 6
Capex / Sales - 21.74% 19.61% - 6.61% 6.13% 2.93%
Announcement Date 02/02/21 09/02/22 14/03/23 02/02/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for T&L Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
65,300 KRW
Average target price
71,500 KRW
Spread / Average Target
+9.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
T&L CO., LTD. Stock T&L Co., Ltd.
+63.25% 386M
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.96% 181B
MEDTRONIC PLC Stock Medtronic plc
+2.64% 112B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-2.62% 67.92B
DEXCOM, INC. Stock DexCom, Inc.
+4.82% 50.1B
CENCORA, INC. Stock Cencora, Inc.
+7.94% 44.27B
HOYA CORPORATION Stock Hoya Corporation
+9.39% 40.41B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+24.38% 31.95B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-0.02% 25.82B
TERUMO CORPORATION Stock Terumo Corporation
+17.27% 25.29B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. A340570 Stock
  4. Financials T&L Co., Ltd.